GlassScriptPhysician profile
Nicholas Kim
NPI 1427507680
$9,977.63
in general payments reported to CMS, 2019-2025
27 companies · $3,117 in 2025
The $3,117 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $771 · 2022: $1,137 · 2023: $1,648 · 2024: $3,305 · 2025: $3,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,825 · Education: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,825.13 |
| Education | $244.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,327.77 | 2021-2025 | Tremfya, Simponi, Remicade |
| Regeneron Healthcare Solutions, INC. | $1,035.90 | 2021-2025 | Dupixent, Libtayo |
| Abbvie INC. | $1,029.75 | 2021-2025 | |
| Dermavant Sciences, INC. | $635.06 | 2023-2024 | Vtama |
| Genzyme Corporation | $625.84 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $567.87 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $449.89 | 2023-2025 | Zoryve |
| Ucb, INC. | $435.96 | 2021-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $434.99 | 2021-2025 | Jublia, Siliq, Duobrii |
| Lilly USA, LLC | $417.68 | 2022-2025 | Olumiant, Taltz, Ebglyss |
| Amgen INC. | $398.41 | 2022-2025 | Otezla, Enbrel, Otezla |
| Incyte Corporation | $376.03 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $347.51 | 2022-2025 | Ilumya, Blu-U, Winlevi |
| Leo Pharma INC. | $340.30 | 2022-2025 | Adbry, Anzupgo |
| Pfizer INC. | $294.92 | 2021-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $279.27 | 2024-2025 | Vtama, Nexplanon |
| Galderma Laboratories, L.P. | $277.41 | 2022-2025 | Nemluvio, Aklief |
| E.R. Squibb & Sons, L.L.C. | $232.45 | 2022-2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $199.73 | 2025 | |
| Kyowa Kirin, INC. | $88.37 | 2024-2025 | Poteligeo |
| Botanix Sb INC | $57.64 | 2025 | Sofdra |
| Hill Dermaceuticals, INC. | $35.95 | 2022 | |
| Almirall LLC | $24.58 | 2022 | |
| Organogenesis INC. | $22.22 | 2025 | Puraply Wound Matrix |
| Dermira, INC. | $17.47 | 2021 | |
| Nabriva Therapeutics, Plc | $14.51 | 2022 | |
| Genentech USA, INC. | $10.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.